Photo by ricochet64/Shutterstock.com

The U.S. Court of Appeals for the Federal Circuit has just made it more difficult to sue generic drug makers for patent infringement in Delaware and New Jersey.

The D.C.-based appellate court ruled Thursday that, under the U.S. Supreme Court's 2017 TC Heartland venue ruling, branded pharmaceuticals can bring Hatch-Waxman Act suits only where a generic pharma submitted its Abbreviated New Drug Application (ANDA)—typically, either the generic's corporate headquarters or Food and Drug Administration offices in Maryland.